Hyperbilirubinemia following exposure to pancuronium bromide in newborns.
We investigated the risk of hyperbilirubinemia in relation to the administration of pancuronium bromide among newborn infants requiring mechanical ventilation. One hundred and twenty-nine infants treated with pancuronium were compared to 129 infants who were never exposed, matched on ventilatory status, hospital, birthweight, initial total serum bilirubin, and date of hospital discharge. Overall, the adjusted summary relative risk (RR) for hyperbilirubinemia among pancuronium-exposed infants compared to nonexposed infants was 1.2 (95% confidence interval 1.1-1.4). The risk was greatest among exposed infants during the 4 days following the last dose of pancuronium (RR = 1.4; 1.0-1.8). These data suggest that the use of pancuronium in sick newborns may be associated with an increased risk of clinically important hyperbilirubinemia.
Freeman
J
J
Slone Epidemiology Unit, School of Public Health, Boston University School of Medicine, Mass.
Lesko
S M
SM
Mitchell
A A
AA
Epstein
M F
MF
Shapiro
S
S
D001663:Bilirubin / Q000097:blood; D005260:Female; D006801:Humans; D006932:Hyperbilirubinemia / Q000139:chemically induced*; D007231:Infant, Newborn; D008297:Male; D010197:Pancuronium / Q000009:adverse effects*; D012121:Respiration, Artificial; D012307:Risk Factors
D010197:Pancuronium; D001663:Bilirubin